Robert J. More - Oct 19, 2023 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
Director
Signature
/s/ Sung Lee, Attorney-in-Fact
Stock symbol
VIR
Transactions as of
Oct 19, 2023
Transactions value $
$0
Form type
4
Date filed
10/20/2023, 02:15 PM
Previous filing
Jun 2, 2023
Next filing
May 31, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Other $0 -6.41K -14.21% $0.00 38.7K Oct 19, 2023 Direct F1
transaction VIR Common Stock Other $0 +6.41K +1.31% $0.00 496K Oct 19, 2023 See footnote F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred for no consideration to APNG 1 in connection with the vesting of an RSU award. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1. However, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.
F2 Shares transferred for no consideration to APNG 1 upon vesting of an RSU award held by the Reporting Person for the benefit of APNG 1.
F3 The shares are held by APNG 1. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. The Reporting Person may be deemed to beneficially own the shares held by APNG 1, and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.